Scientific Program

Please note:  All presentations indicated with * are available for on demand viewing only until Monday, November 21, 2022.  Those underlined were live-steamed only and not avaiable in this on demand program.

DAY 1 – Friday, November 11, 2022
All timing in CET
11:00-11:10 Welcome address: Naveen Pemmaraju, USA, Claire Harrison, UK & Ruben Mesa, USA
Congress Co-Chairs
11:10-13:05 Session 1: Polycythemia Vera in 2022 and beyond
Moderator: Laura Michaelis, USA
11:10-11:15 Welcome from the moderator
11:15-11:35 Debate: Standard of care in PV
11:15-11:25 IFN: Richard Silver, USA
11:25-11:35 HU, other: Brady Stein, USA
11:35-11:55 Treatment updates: Ropeginterferon in 2022:
Jean-Jacques Kiladjian, France
11:55-12:15 Clinical trial update: PTG-300/Rusfertide: from bench to bedside Hepcidin Mimetics in PV:
Ronald Hoffman, USA
12:15-12:35 Debate: Future directions in PV
12:15-12:25 Molecular risk stratification, better understanding of MPN stem cell biology will guide future therapy approaches:
Jerry Spivak, USA
12:25-12:35 Clinical factors, sustained HCT reduction, symptom burden, thrombosis/ bleeding risk to guide future therapy options in PV:
Laura Michaelis, USA
12:35-13:05 Panel discussion
13:05-14:50 Session 2: Essential thrombocytosis: state-of-the-art
Moderator: Claire Harrison, UK
13:05-13:10 Welcome from the moderator
13:10-13:30 Debate: Low-dose ASA in ET: standard of care in ET
13:10-13:20 Pro: Lucia Masarova, USA
13:20-13:30 Con: Alessandro Vannucchi, Italy
13:30-13:50 Higher risk ET: state-of-the-art management in 2022:
Claire Harrison, UK
13:50-14:10 CALR mutations: from 2013 to present – a review:
Ian Hitchcock, UK
14:10-14:30 CALR and ET: Role of immunotherapy as future directions/novel approaches:
Ann Mullally, USA
14:30-14:50 Panel discussion
14:50-15:00 Program pause
15:00-17:30 Session 3: Myelofibrosis: current and novel approaches in a rapidly developing field
Moderator: Naveen Pemmaraju, USA
15:00-15:05 Welcome from the moderator
15:05-15:25 Early/lower risk MF: treatment options and approach:
Ruben Mesa, USA
15:25-15:45 Int/higher risk MF: current treatment options in 2022:
Srdan Verstovsek, USA
15:45-16:05 Anemia in MF: emerging area for novel approaches:
Naveen Pemmaraju, USA
16:05-16:25 Debate: Novel therapies in MF as single agents beyond JAKi
16:05-16:15 Importance of overall survival as endpoints, novel agents:
John Mascarenhas, USA
16:15-16:25 Importance of spleen volume/Sxs burden, reduction of novel agents:
Prithviraj Bose, USA
16:25-16:45 Debate: Novel therapies in combinations in MF: an emerging new era
16:25-16:35 With JAKi – important steps forward in patient management:
Naveen Pemmaraju, USA
16:35-16:45 In MF: Beware of toxicities, complications to monitor for as we enter combination era:
Aaron Gerds, USA
16:45-17:05 Debate: SCT in MF: European and American perspectives:
16:45-16:55 US: Tania Jain, USA
16:55-17:05 * European: Ibrahim Yakoub-Agha, France
17:05-17:30 Panel discussion
17:30-19:15 Session 4: AYA MPNs: pregnancy, thromboses, unique aspects
Moderator: Gabriela Hobbs, USA
17:30-17:35 Welcome from the moderator
17:35-17:55 * Pediatric and MPN AYAs: an overview and cohort experience:
Nicole Kucine, USA
17:55-18:15 Pregnancy, fertility and hormone therapy: state-of-the-art considerations:
Susan Robinson, UK
18:15-18:35 Young patients with MPNs: unique considerations in thromboses:
Gabriela Hobbs, USA
18:35-18:55 Pediatric AYA MPN: European perspective:
Jean-Jacques Kiladjian, France
18:55-19:15 Panel discussion
DAY 2- Saturday, November 12, 2022
All timing in CET
11:00-11:10 Welcome: Naveen Pemmaraju, USA, Claire Harrison, UK & Ruben Mesa, USA
Congress Co-Chairs
11:10-13:00 Session 5: Rare MPNs – Focus on emerging subtypes
Moderator: Deepti Radia, UK
11:10-11:15 Welcome from the moderator
11:15-11:35 Updates in the classification of eosinophilic and mast cell disorders:
Jason Gotlib, USA
11:35-11:55 Aggressive SM: emerging therapy options:
Deepti Radia, UK
11:55-12:15 Debate: MDS/MPN overlap syndromes: CMML
11:55-12:05 US perspective: Mrinal Patnaik, USA
12:05-12:15 European perspective: Daniel Wiseman, UK
12:15-12:35 8p11 Syndrome /MLN eosinophilia: emerging targeted approaches:
Andreas Reiter, Germany
12:35-13:00 Panel discussion
13:00-14:50 Session 6: CHIP and inflammation in MPNs
Moderator: Angela Fleischman, USA
13:00-13:05 Welcome from the moderator
13:05-13:25 * CHIP and MPNs – 2022 report:
David Steensma, USA
13:25-13:45 Diet, Inflammation and MPNs:
Angela Fleischman, USA
13:45-14:05 Debate: Future directions: inflammation in MPNs
13:45-13:55 *Emphasis on CHIP, prior conditions, molecular markers leading to MPN:
Steffen Koschmieder, Germany
13:55-14:05 Emphasis on novel, molecular, translational markers in MF:
Stephen Oh, USA
14:05-14:25 MPN mutations start younger than we thought: in-utero observations:
Jyoti Nangalia, UK
14:25-14:50 Panel discussion
14:50-15:00 Program pause
15:00-16:50 Session 7: Role of future of pathology and molecular markers in MPNs: current and future directions
Moderator: Naveen Pemmaraju, USA
15:00-15:05 Welcome from the moderator
15:05-15:25 Debate: Role of next generation sequencing in MPNs: from bench to bedside
15:05-15:15 Molecular markers heralding time of progression from MPN to AML: checking molecular panel at time of clonal evaluation:
Raajit Rampal, USA
15:15-15:25 Molecular markers at baseline MPN dx: important for initial assessment for all patient for risk stratification:
Andrew Kuykendall, USA
15:25-15:45 Debate: Role of expert hematopathologist in MPNs: virtual second opinions, digital pathology, molecular phenotyping
15:25-15:35 WHO classification – new updates from a hemapathologist’s perspective: what’s news/ what’s changed:
Sanam Loghavi, USA
15:35-15:45 A day in the life of a hemapathologist working up a case of MF: what is same, what is new?
Kamran Mirza, USA
15:45-16:05 WHO classification in MPNs: an evolving paradigm:
Joseph Khoury, USA
16:05-16:25 AI-based morphological fingerprinting in MPNs:
Daniel Royston, UK
16:25-16:50 Panel discussion
16:50-18:30 Session 8: What are best practices for MPN care in 2022 across the world?
Moderator: Ruben Mesa, USA
16:50-16:55 Welcome from the moderator
16:55-17:05 How to build and maintain a rare disease clinical and research program:
Naveen Pemmaraju, USA
17:05-17:25 MPN service infrastructure – running a service line: nursing/research/virtual:
Raajit Rampal, USA
17:25-17:45 MPN center needs and future directions: a model system in the UK as case study:
Claire Harrison, UK
17:45-18:05 MPN program clinical/translational development strategies future directions:
Ruben Mesa, USA
18:05-18:30 Panel discussion
18:30-18:45 Closing remarks: Naveen Pemmaraju, USA, Claire Harrison, UK & Ruben Mesa, USA
Congress Co-Chairs